Complete Filing Data
Nasus Pharma Ltd reported Proceeds From Convertible Debt of $435.0 thousand for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Nasus Pharma Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research And Development Expense | $2.2M | $335.0K | $567.0K |
| Other Nonoperating Expense | $27.0K | $2.0K | $28.0K |
| Operating Income Loss | -$4.9M | -$1.1M | -$1.1M |
| Operating Expenses | $4.9M | $1.1M | $1.1M |
| Net Income Loss | -$5.9M | -$1.5M | -$1.1M |
| Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity | -$51.0K | $20.0K | -$46.0K |
| Income Loss From Continuing Operations | -$5.8M | -$1.6M | -$1.0M |
| General And Administrative Expense | $2.7M | $743.0K | $580.0K |
| Interest Expense Nonoperating | -$78.0K | $29.0K | $49.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $2.8M | -$3.2M | -$3.8M | -$2.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $1.3M | $311.0K | $210.0K | $171.0K |
| Restricted Cash | $54.0K | $27.0K | $17.0K | |
| Cash And Cash Equivalents At Carrying Value | $1.2M | $284.0K | $193.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $980.0K | $101.0K | $39.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.3M | $311.0K | $210.0K | |
| Retained Earnings Accumulated Deficit | -$18.5M | -$12.7M | ||
| Prepaid Expense And Other Assets Current | $515.0K | $146.0K | ||
| Offering Cost Included In Accrued Expense And Other Current Liabilities | $55.0K | $30.0K | ||
| Liabilities Of Disposal Group Including Discontinued Operation Current | $483.0K | $489.0K | ||
| Liabilities Current | $2.2M | $3.9M | ||
| Liabilities And Stockholders Equity | $5.0M | $717.0K | ||
| Liabilities | $2.2M | $3.9M | ||
| Cash Provided By Used In Operating Activities Discontinued Operations | -$56.0K | -$4.0K | -$47.0K | |
| Assets Current | $4.9M | $457.0K | ||
| Assets | $5.0M | $717.0K | ||
| Accounts Payable Current | $829.0K | $651.0K | ||
| Accounts Payable And Other Accrued Liabilities Current | $806.0K | $987.0K | ||
| Convertible Debt Current | $1.8M | |||
| Common Stock Value | $20.0K | |||
| Accrued Interest On Shortterm Debt From Shareholders | $29.0K | $49.0K | ||
| Deferred Offering Costs Non Current | $260.0K | |||
| Conversion Of Shortterm Debt From Shareholders Safes | $636.0K | |||
| Property Plant And Equipment Net | $14.0K | |||
| Operating Lease Rightofuse Assets Acquired Through Lease Liability | $145.0K | |||
| Operating Lease Right Of Use Asset | $135.0K | |||
| Operating Lease Liability Noncurrent | $73.0K | |||
| Operating Lease Liability Current | $45.0K | |||
| Deposits Assets Current | $3.0M | |||
| Deferred Offering Coststransferred To Additional Paidincapital | $260.0K | |||
| Accrued Interest On Short Term Deposit | $49.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financing Cash Flow * | $8.9M | $770.0K | $1.1M | |
| Investing Cash Flow * | -$3.0M | |||
| Operating Cash Flow * | -$4.9M | -$665.0K | -$1.0M | |
| Proceeds From Convertible Debt | $435.0K | $1.0M | $995.0K | $966.0K |
| Share Based Compensation | $447.0K | $10.0K | $39.0K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $370.0K | -$88.0K | -$12.0K | |
| Increase Decrease In Accrued Liabilities | -$182.0K | $322.0K | $271.0K | |
| Increase Decrease In Accounts Payable | $152.0K | -$5.0K | -$116.0K | |
| Effect Of Exchange Rates | $8.0K | $4.0K | -$13.0K | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$8.0K | -$4.0K | $13.0K | |
| Payments Of Debt Issuance Costs | $230.0K | |||
| Proceeds From Short Term Debt | $60.0K | |||
| Proceeds From Issuance Of Common Stock | $8.5M | |||
| Payments To Acquire Property Plant And Equipment | $14.0K | |||
| Increase Decrease In Operating Lease Liability | -$27.0K | |||
| Increase Decrease In Noncash Lease Expense | $12.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 8.0M | 7.0M | 6.9M |
| Weighted Average Number Of Diluted Shares Outstanding | 8.0M | 7.0M | 7.1M |
| Earnings Per Share Diluted | $-0.72 | $-0.22 | $-0.20 |
| Earnings Per Share Basic | $-0.72 | $-0.22 | $-0.15 |
| Common Stock Shares Issued | 9.0M | 7.4M | |
| Common Stock Shares Authorized | 22.8M | 13.3M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.01 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $447.0K | $10.0K | $39.0K |
| Changes In Fair Value Of Convertible Securities | $952.0K | $443.0K | -$219.0K |
| Change In Fair Value Of Convertible Securities | $952.0K | $443.0K | -$219.0K |
| Additional Paid In Capital | $21.3M | $9.4M | |
| Stock Issued During Period Value Conversion Of Convertible Securities | $3.2M | $2.1M | |
| Stock Issued During Period Value New Issues | $8.2M | $636.0K | |
| Conversion Of Safes Into Ordinary Shares | 3.2M | 2.1M | |
| Short Term Deposit | $3.0M |
Most recent annual filing with the SEC: March 25, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.